News

Most recently, Mr Orville served as vice president of global sales for NextGen Sciences, an Ann Arbor, Michigan-based biomarker testing provider. Prior to joining NextGen, Mr Orville was

Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent company, DFB Pharmaceuticals, and other shareholders for $95 million.

The Phase III clinical trial results on which this approval was based demonstrated that Abraxane doubled the response rate and significantly prolonged progression-free survival and overall survival versus

Preclinical in-vitro and in-vivo studies of RDEA119 have demonstrated synergistic activity across multiple tumor types when RDEA119 is used in combination with other anticancer agents, including sorafenib. This

The Phase II, multi-center, randomized, double-blind, placebo-controlled study is designed to assess the safety and efficacy of multiple doses of ACE-011 in multiple myeloma patients with osteolytic bone

Nicholas Stergis, CEO of Adeona, said: “As previously announced, we are pleased to have completed our corporate name and ticker symbol change. Our primary focus is toward the

Through the collaboration, the companies plan to work together to advance innovation in the development of probiotic-enhanced nutrition bars and powdered products. Nellson’s technical expertise in the area

The decision by the German Federal Court found that CoreValve’s ReValving system for transcatheter aortic valve replacement does not infringe any of the claims of the Andersen patent

The clinical study analyzed paraffin embedded tissue samples from 476 prostate cancer patients collected at four major clinical centers in Europe and the US who had undergone radical